Merck to Present Phase 3 CORALreef and Phase 2 CADENCE Results at ACC.26
Merck will present new clinical data at ACC.26 from March 28-30 covering positive Phase 3 CORALreef AddOn results for oral PCSK9 inhibitor enlicitide versus ezetimibe and bempedoic acid in statin-treated hypercholesterolemia patients. Merck will share Phase 2 CADENCE results for WINREVAIR (sotatercept-csrk) in combined pre- and post-capillary pulmonary hypertension.
1. Merck to Present Cardio-Pulmonary Pipeline Data at ACC.26
Merck will share new clinical findings from its cardio-pulmonary portfolio during the American College of Cardiology’s Annual Scientific Session (ACC.26) from March 28 to 30. These presentations underscore the company’s focus on innovative treatments for hypercholesterolemia and pulmonary hypertension.
2. Positive Phase 3 and Phase 2 Trial Outcomes
The Phase 3 CORALreef AddOn trial demonstrated enlicitide’s efficacy versus ezetimibe and bempedoic acid in statin-treated adults with hypercholesterolemia, highlighting potential for an oral PCSK9 inhibitor. The Phase 2 CADENCE trial showed favorable safety and efficacy for WINREVAIR (sotatercept-csrk) in combined pre- and post-capillary pulmonary hypertension.